HK2 and neoplasm: The combined exposure of HK2 (3-bromopyruvate) and PDI inhibitors (bacitracin) resulted in the reduction of microvessel densities, (a surrogate marker for tumor angiogenesis), in an in vivo model of hepatocellular carcinoma [160].